SAN DIEGO, April 3, 2020 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) today announced that due to the
emerging public health impact of the coronavirus
outbreak (COVID-19), to support the health and well-being of
our employees and stockholders, and to comply with the State of California's stay at home order, its
Board of Directors has approved a change in the location of its
2020 Annual Meeting of Stockholders to a virtual-only shareholder
meeting instead of an in-person meeting. As previously
announced, the Annual Meeting will be held on Thursday, April 30, 2020 at 8:00 a.m. local time. Stockholders will not be
able to attend the Annual Meeting physically in person.
As described in the proxy materials for the Annual Meeting
previously distributed, stockholders are entitled to participate in
the Annual Meeting if they were a stockholder as of the close of
business on March 2, 2020, the record
date, or hold a legal proxy for the meeting provided by their bank,
broker, or nominee.
To be admitted to the Annual Meeting at
www.virtualshareholdermeeting.com/HALO2020, stockholders must enter
the control number found on the proxy card, voting instruction form
or notice they previously received. Stockholders may vote during
the Annual Meeting by following the instructions available on the
meeting website during the meeting. The meeting's virtual
attendance format will provide stockholders the ability to
participate and ask questions in writing during the meeting.
Whether or not they plan to attend the Annual Meeting, our
stockholders are urged to vote and submit their proxy in advance of
the meeting by one of the methods described in the proxy materials
for the Annual Meeting. The proxy card included with the proxy
materials previously distributed will not be updated to reflect the
change in location and format and may continue to be used to vote
your shares in connection with the Annual Meeting.
About Halozyme
Halozyme Therapeutics, Inc. is a
biopharma technology platform company that provides innovative and
disruptive solutions with the goal of improving patient experience
and outcomes. Our proprietary enzyme rHUPH20 is used to facilitate
the delivery of injected drugs and fluids. We license our
technology to biopharmaceutical companies to collaboratively
develop products that combine our ENHANZE® drug delivery
technology with the collaborators' proprietary compounds. Halozyme
is headquartered in San Diego. For
more information visit www.halozyme.com.
Contact:
Al Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/halozyme-announces-change-of-location-of-annual-stockholders-meeting-301034634.html
SOURCE Halozyme Therapeutics, Inc.